Skip to main content

Migraine drug could halve the length of attacks, study shows

By The Guardian  
   November 30, 2017

The research revealed that by months four to six, at least a 50% reduction in mean migraine days per month was achieved for just over 43% of patients injected under the skin with 70-mg of erenumab each month, while half of patients injected with the higher dose of 140-mg had such results. However, those given a placebo also saw benefits, with 26.6% of participants in this group experiencing such a reduction.

Full story


Get the latest on healthcare leadership in your inbox.